To further confirm whether NF-kB and FOXO1 signaling pathway participate in CCL18/PITPNM3 axis regulating the function of ICC cells, we treated HCCC-9810 cells using the activator of NF-kB (Asatone) or FOXO1 inhibitor (AS1842856) combined with CCL18. This evidence concerns the gene NFKB1 and intrahepatic cholangiocarcinoma.